Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host David Gura talks to Bloomberg reporters Naomi Kresge and Amber Tong about what comes next bit.ly/4dW9xD3 | Bloomberg
1:47
Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host David Gura talks to Bloomberg reporters Naomi Kresge and Amber Tong about what comes next bit.ly/4dW9xD3 | Bloomberg
1.2K views4 months ago
FacebookBloomberg
See more
Static thumbnail place holder